You could be right. Management definitely know the reasons, but...

You could be right. Management definitely know the reasons, but are not willing to divulge to the market until they receive 'clarification' from HREC.

I had a look at some of the past presentations and announcements and got the impression that NSB are lacking data and trying their best to leverage data published elsewhere. Maybe NSB simply don't have enough data to commence a P1 trial.

They were also wanting to recruit 88 patients - that's a lot of patients for a P1.

Some of the other data also showed neuronal regeneration, even in the healthy controls - I think they were cell studies I was looking at. This could be potentially problematic since NSB don't know what the potential long term consequences are of increasing neuronal growth in healthy people.

I hope you guys get answers sooner rather than later.